# Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.

> **NCT06615830** · — · NOT_YET_RECRUITING · sponsor: **Prof. Dr. med. Dres. h.c. Jan Schmidt, MME** · enrollment: 185 (estimated)

## Conditions studied

- Pancreas Neoplasms
- Pancreatic Neoplasms
- Pancreatic Cancer Metastatic
- Pancreatic Adenocarcinoma Metastatic

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06615830
- **Lead sponsor:** Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2030-12
- **Final completion:** 2031-01
- **Target enrollment:** 185 (ESTIMATED)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06615830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06615830, "Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06615830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*